BioCentury
ARTICLE | Financial News

Repare launches with $68M series A

June 23, 2017 7:39 PM UTC

On June 22, cancer company Repare Therapeutics Inc. (Montreal, Quebec) launched with a $68 million series A round. Versant Ventures, which founded the company, co-led the round with MPM Capital. Also participating were Fonds de solidarité FTQ which invested $8.75 million, the Celgene Switzerland LLC affiliate of Celgene Corp. (NASDAQ:CELG) and BDC Capital’s Healthcare Venture Fund.

The newco is using a CRISPR-based platform to identify novel targets that have synthetic lethal interactions with specific cancer-associated genomic defects. Synthetic lethality is a phenomenon in which genomic or pharmacologically induced defects that are tolerated individually become lethal when combined...